January 8, 2025 03:45 PM EST

Revance weighs competing buyout offer amid push from original bidder

Nicole DeFeudis

Editor

Revance Therapeutics said Wednesday it will have talks with Teoxane on its bid to take over Revance’s company. But Crown Laboratories — the initial bidder …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Revance weighs competing buyout offer amid push from original bidder

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

Pfizer, GSK add risk of Guillain-Barré to RSV vaccine labels at FDA's request

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Re­vance weighs com­pet­ing buy­out of­fer amid push from orig­i­nal bid­der

Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Revance weighs competing buyout offer amid push from original bidder